US2011104166A1PendingUtilityA1

Methods and Compositions for Treating Polyps

45
Individually held — no corporate assignee on recordPriority: Jan 18, 2008Filed: Jan 16, 2009Published: May 5, 2011
Est. expiryJan 18, 2028(~1.5 yrs left)· nominal 20-yr term from priority
Inventors:Konstantina StankovicRalph Metson
A61P 35/00A61P 29/00C07K 16/40C07K 14/00C12Q 2600/158A61P 11/06C12N 15/1137A61K 31/41C12N 15/1135C12Q 1/6883
45
PatentIndex Score
0
Cited by
0
References
0
Claims

Abstract

The invention relates generally to methods and compositions for treating sinusitis, asthma, or polyps. The invention also relates to methods and compositions for treating nasal polyps.

Claims

exact text as granted — not AI-modified
1 . A method for downregulating periostin, downregulating protein phosphatase 1, downregulating MET, upregulating prolactin-induced protein, or upregulating zinc alpha2-glycoprotein in polyp tissue, the method comprising delivering at least one agent selected from the group consisting of an antagonist of periostin, an antagonist of protein phosphatase 1, an antagonist of MET, an agonist of prolactin-induced protein, and an agonist of zinc alpha2-glycoprotein to the polyp tissue in an amount sufficient to downregulate periostin, down-regulate protein phosphatase 1, downregulate MET, upregulate prolactin-induced protein, upregulate zinc alpha2-glycoprotein, or a combination thereof in the polyp tissue. 
     
     
         2 . (canceled) 
     
     
         3 . The method of  claim 1 , wherein the antagonist of periostin is selected from the group consisting of an anti-periostin antibody, valsartan, and a small interfering RNA. 
     
     
         4 . (canceled) 
     
     
         5 . The method of  claim 1 , wherein the antagonist of protein phosphatase 1 is selected from the group consisting of a peptide comprising an amino acid sequence of MEPDNSPRKIQFTVPLLEPHLDPEAAEQIRRRRPTPATLVLTSDQSSPEIDEDRIPNSLLKS TLSMSPRQRKKMTRTTPTMKELQTMVEHHLGQQKQGEEPEGATESTGNQESCPPGIPD TGSASRPDTPGTAQKSAESNPKTQEQCGVEPRTEDSSAHMLPLDSQGASLV (SEQ ID NO:1), a peptide comprising an amino acid sequence of MAASTASHRPIKGILKNKTSSTSSRVASAEQPRGSVDEELSKKSQKWDEMNILATYHPA DKDYGLMKIDEPSTPYHSMIGDDDDAYSDTETTEAMTPDTLAKKLAAAEGSEPKYRIRE QESSGEEDSDLSPEEREKKRQFEMKRKLHYNEGLNIKLARQLISKDLHDDEEDEEMSET ADGESMNTEESNQGSTPSDQRQNKSQSS (SEQ ID NO:2), dopamine- and cyclic AMP-regulated phosphoprotein (DARPP-32), a protein phosphatase inhibitor, an anti-protein phosphatase 1 antibody, and a small interfering RNA. 
     
     
         6 .- 9 . (canceled) 
     
     
         10 . The method of  claim 1 , wherein the antagonist of MET is selected from the group consisting of a small interfering RNA, an anti-MET antibody, and a tyrosine kinase inhibitor. 
     
     
         11 .- 12 . (canceled) 
     
     
         13 . The method of  claim 1 , wherein the agonist of prolactin-induced protein is selected from the group consisting of exogenous prolactin-induced protein and a stimulator of prolactin-induced protein production. 
     
     
         14 .- 15 . (canceled) 
     
     
         16 . The method of  claim 1 , wherein the agonist of zinc alpha2-glycoprotein is selected from the group consisting of exogenous zinc alpha2-glycoprotein and a stimulator of zinc alpha2-glycoprotein production. 
     
     
         17 . (canceled) 
     
     
         18 . A method for treating a polyp, the method comprising administering to a subject having or suspected of developing a polyp an agent selected from the group consisting of an antagonist of periostin, an antagonist of protein phosphatase 1, an antagonist of MET, an agonist of prolactin-induced protein, and an agonist of zinc alpha2-glycoprotein in an amount sufficient to attenuate growth of the polyp or to regress the polyp. 
     
     
         19 . The method of  claim 18 , wherein the polyp comprises a nasal polyp. 
     
     
         20 . The method of  claim 18 , wherein the subject has a disorder selected from the group consisting of sinusitis, chronic rhinosinusitis, asthma, and aspirin-sensitive asthma. 
     
     
         21 .- 24 . (canceled) 
     
     
         25 . The method of  claim 18 , wherein the subject is a mammal. 
     
     
         26 . (canceled) 
     
     
         27 . The method of  claim 18 , wherein the agent is administered locally or systemically. 
     
     
         28 .- 29 . (canceled) 
     
     
         30 . The method of  claim 18 , wherein the antagonist of periostin is selected from the group consisting of an anti-periostin antibody, valsartan, and a small interfering RNA. 
     
     
         31 . (canceled) 
     
     
         32 . The method of  claim 18 , wherein the antagonist of protein phosphatase 1 is selected from the group consisting of a peptide comprising an amino acid sequence of MEPDNSPRKIQFTVPLLEPHLDPEAAEQIRRRRPTPATLVLTSDQSSPEIDEDRIPNSLLKS TLSMSPRQRKKMTRTTPTMKELQTMVEHHLGQQKQGEEPEGATESTGNQESCPPGIPD TGSASRPDTPGTAQKSAESNPKTQEQCGVEPRTEDSSAHMLPLDSQGASLV (SEQ ID NO:1), a peptide comprising an amino acid sequence of MAASTASHRPIKGILKNKTSSTSSRVASAEQPRGSVDEELSKKS QKWDEMNILATYHPA DKDYGLMKIDEPSTPYHSMIGDDDDAYSDTETTEAMTPDTLAKKLAAAEGSEPKYRIRE QESSGEEDSDLSPEEREKKRQFEMKRKLHYNEGLNIKLARQLISKDLHDDEEDEEMSET ADGESMNTEESNQGSTPSDQRQNKSQSS (SEQ ID NO:2), dopamine- and cyclic AMP-regulated phosphoprotein (DARPP-32), a protein phosphatase inhibitor, an anti-protein phosphatase 1 antibody, and a small interfering RNA. 
     
     
         33 .- 36 . (canceled) 
     
     
         37 . The method of  claim 18 , wherein the antagonist of MET is selected from the group consisting of a small interfering RNA, an anti-MET antibody, and a tyrosine kinase inhibitor. 
     
     
         38 .- 39 . (canceled) 
     
     
         40 . The method of  claim 18 , wherein the agonist of prolactin-induced protein is selected from the group consisting of exogenous prolactin-induced protein and a stimulator of prolactin-induced protein production. 
     
     
         41 .- 42 . (canceled) 
     
     
         43 . The method of  claim 18 , wherein the agonist of zinc alpha2-glycoprotein is selected from the group consisting of exogenous zinc alpha2-glycoprotein and a stimulator of zinc alpha2-glycoprotein production. 
     
     
         44 . (canceled) 
     
     
         45 . A method for treating sinusitis or asthma, the method comprising administering to a subject having or suspected of developing sinusitis at least one agent selected from the group consisting of an antagonist of periostin, an antagonist of protein phosphatase 1, an antagonist of MET, an agonist of prolactin-induced protein, and an agonist of zinc alpha2-glycoprotein in an amount sufficient to alleviate a symptom of the sinusitis or asthma. 
     
     
         46 . (canceled) 
     
     
         47 . The method of  claim 45 , wherein the symptom comprises a nasal polyp. 
     
     
         48 . The method of  claim 45 , wherein the subject has chronic rhinosinusitis or aspirin-sensitive asthma. 
     
     
         49 .- 50 . (canceled) 
     
     
         51 . The method of  claim 45 , wherein the subject is a mammal. 
     
     
         52 . (canceled) 
     
     
         53 . The method of  claim 45 , wherein the agent is administered locally or systemically. 
     
     
         54 . (canceled) 
     
     
         55 . The method of  claim 45 , wherein the antagonist of periostin is selected from the group consisting of an anti-periostin antibody, valsartan, and a small interfering RNA. 
     
     
         56 . The method of  claim 45 , wherein the antagonist of protein phosphatase 1 is selected from the group consisting of a peptide comprising an amino acid sequence of MEPDNSPRKIQFTVPLLEPHLDPEAAEQIRRRRPTPATLVLTSDQSSPEIDEDRIPNSLLKS TLSMSPRQRKKMTRTTPTMKELQTMVEHHLGQQKQGEEPEGATESTGNQESCPPGIPD TGSASRPDTPGTAQKSAESNPKTQEQCGVEPRTEDSSAHMLPLDSQGASLV (SEQ ID NO:1), a peptide comprising an amino acid sequence of MAASTASHRPIKGILKNKTSSTSSRVASAEQPRGSVDEELSKKSQKWDEMNILATYHPA DKDYGLMKIDEPSTPYHSMIGDDDDAYSDTETTEAMTPDTLAKKLAAAEGSEPKYRIRE QESSGEEDSDLSPEEREKKRQFEMKRKLHYNEGLNIKLARQLISKDLHDDEEDEEMSET ADGESMNTEESNQGSTPSDQRQNKSQSS (SEQ ID NO:2), dopamine- and cyclic AMP-regulated phosphoprotein (DARPP-32), a protein phosphatase inhibitor, an anti-protein phosphatase 1 antibody, and a small interfering RNA. 
     
     
         57 .- 59 . (canceled) 
     
     
         60 . The method of  claim 45 , wherein the antagonist of MET is selected from the group consisting of a small interfering RNA, an anti-MET antibody, and a tyrosine kinase inhibitor. 
     
     
         61 . (canceled) 
     
     
         62 . The method of  claim 45 , wherein the agonist of prolactin-induced protein is selected from the group consisting of exogenous prolactin-induced protein and a stimulator of prolactin-induced protein production. 
     
     
         63 . (canceled) 
     
     
         64 . The method of  claim 45 , wherein the agonist of zinc alpha2-glycoprotein is selected from the group consisting of exogenous zinc alpha2-glycoprotein and a stimulator of zinc alpha2-glycoprotein production. 
     
     
         65 . (canceled)

Join the waitlist — get patent alerts

Track US2011104166A1 — get alerts on status changes and closely related new filings.

We store only your email — no account needed. See our privacy policy.